The role of otoacoustic emissions in the identification and monitoring of cisplatin-induced ototoxicity

Journal of Audiological Medicine

Volumn 8, Issue 1, 1999, Pages 1-17

  Sockalingam, Ravichandran ^a   Murdoch, Bruce ^a   Charles, Bruce ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cisplatin; Otoacoustic emissions; Ototoxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CISPLATIN; LOOP DIURETIC AGENT;

CANCER CHEMOTHERAPY; EVOKED BRAIN STEM AUDITORY RESPONSE; HUMAN; NONHUMAN; OTOACOUSTIC EMISSION; OTOTOXICITY; PURE TONE AUDIOMETRY; REVIEW; SCREENING;

EID: 0032943922     PISSN: 09637133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Anniko M, Sobin A. Cisplatin: Evaluation of its ototoxic potential. American Journal of Otorhinolaryngology 1986; 7: 276-93.
2. Balkany T, Telichi FF, McCoy M, Lonsbury-Martin BL, Martin GK. Otoacoustic emissions in otologic practice. American Journal of Otology 1994; 15 (Supp. 1): 29-38.
3. Beal SL, Sheiner LB. NONMEM User's Guides, NONMEM Project Group. San Francisco: University of California, 1989.
4. Beck JA, Maurer J, Welkoborsky HJ, Mann W. Changes of otoacoustic emissions during chemotherapy with cisplatin and fluorouracil. HNO 1992; 40: 123-7.
5. 2 distortion products in man during quinine administration. Scandinavian Audiology 1995; 24: 27-32.
6. Boheim K, Bichler E. Cisplatin-induced ototoxicity: Audiometric findings and experimental cochlear pathology. Archives of Otorhinolaryngology 1985; 242(1): 1-6.
7. Bourne M. Cisplatin ototoxicity: A review of the literature. Australian Journal of Audiology 1984; 6: 33-42.
8. Brock RP, Bellman CS, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: A practical grading system. Medical and Pediatric Oncology 1991; 19: 295-300.
9. Brown, AM, McDowell B, Forge A. Acoustic distortion products can be used to monitor the effects of chronic gentamicin treatment. Hearing Research 1989; 42: 143-156.
10. Brownell WE. Outer hair cell electromotility and otoacoustic emissions. Ear and Hearing 1990; 11(2): 82-92.
11. Buhrer C, Weinel P, Sauter S, Reiter A, Riehm H. Acute deafness in a 4-year-old girl after a single infusion of cis-platinum. Pediatric Hemotology and Oncology 1990; 7: 145-8.
12. Coupland GS, Ponton WC, Eggermont JJ, Bowen JT, Grant MR. Assessment of cisplatin-induced ototoxicity using derived-band ABRs. International Journal of Pediatric Otorhinolaryngology 1991; 22: 237-48.
13. Dreschler WA, Van der Hulst RJ, Tange RA, Urbanus NAM. Role of high-frequency audiometry in the early detection of ototoxicity. Audiology 1989; 28: 211-20.
14. Estrem A, Babin RW, Ryu JH, Moore KC. Cis-diamminedichloroplatinum II ototoxicity in the guinea pig. Otolaryngology, Head and Neck Surgery 1981; 89: 638-45.
15. Evans EF, Klinke R. The effects of intracochlear and systemic administered furosemide on the properties of single cochlear nerve fibres of the cat. Journal of Physiology 1982; 331: 409-27.
16. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, Bagby GC. High-frequency monitoring for early detection of cisplatin ototoxicity. Archives of Otolaryngology, Head and Neck Surgery, 1993; 119: 661-6.
17. Forastiere AA, Takasugi BJ, Baker SR, Wolf GT, Kudla-Hatch V. High dose cisplatin in an advanced head and neck cancer. Cancer Chemotherapy and Pharmacology 1987; 19: 155-8.
18. Grammatica L, Achille G, Cortese M, Casaula M, Mininni F. Cisplatin ototoxicity: The experience of the Oncologic Institute-Bari. Acta Otorhinolaryngoligica Italica 1992; 12: 383-8.
19. Hawkins JE. Drug ototoxicity. In H Autrum (ed.), Handbook of Sensory Physiology. Vol. 5. Berlin: Springer Verlag, 1976, pp. 707-48.
20. Helson L, Okonkwo E, Amton L, Critkovic E. Cis-platinum ototoxicity. Clinical Toxicology 1978; 13: 469-78.
21. Hill J, Speer R, Loeb E, Maclellan A, Hill NO, Khan A. Clinical experience with cis-platinous diamminedichloride. Paper presented at the VII Congress of Chemotherapy, Prague, Czechoslovakia, 1971.
22. Hinojosa R, Riggs LC, Strauss M, Matz G. Temporal bone histopathology of cisplatin ototoxicity. American Journal of Otology 1995; 16(6): 731-40.
23. Hotz MA, Harris PF, Probst R. Otoacoustic emissions: An approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope 1994; 104: 1130-4.
24. Jusko W. Pharmacodynamics of chemotherapeutic effects: Dose-time relationships for phase non-specific drugs. Journal of Pharmaceutical Sciences 1971; 60: 205-27.
25. Kemp DT. Stimulated acoustic emissions from within the human auditory system. Journal of Acoustical Society of America 1978; 64: 1386-91.
26. Kemp DT, Ryan S. The use of transient evoked otoacoustic emissions in neonatal hearing screening programs. Seminars in Hearing 1993; 14: 30-45.
27. Khovles R, Freeman S, Sohmer H. Transient evoked otoacoustic emissions can be recorded in the rat. Hearing Research 1996; 97: 120-6.
28. Kimitsuki T, Nakagawa T, Hisashi K, Komune S, Komiyama S. Cisplatin blocks mechano-electric transducer current in chick cochlear hair cells. Hearing Research 1993; 71: 64-8.
29. Kommune S, Asakuma S, Snow JB. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngology and Head and Neck Surgery 1981; 89: 275-82.
30. Konnishi T, Gupta BN, Prazma J. Ototoxicity of cis dichlorodiammine platinum II in guinea pigs. American Journal of Otolaryngology 1983; 4: 18-26.
31. Kopelman J, Budnick AS, Kramer MB, Sessions RB, Wong GY. Ototoxicity of high-dose cis-platinum by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988; 98: 858-64.
32. Laurell G, Borg E. Ototoxicity of cisplatin in gynaecological cancer patients. Scandinavian Audiology 1988; 17: 241-7.
33. Laurell G, Jungnelius U. High-dose cisplatin treatment: Hearing loss and plasma concentrations. Laryngoscope 1990; 100: 724-34.
34. Laurell G, Engstrom B. The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hearing Research 1989; 38: 27-34.
35. Leh FKV, Wolf W. Platinum complexes: A new class of antineoplastic agents. Journal of Pharmaceutical Sciences 1976; 65, 315-28.
36. McAlpine D, Johnstone, BM. The ototoxic mechanism of cisplatin. Hearing Research 1990; 47: 191-204.
37. McHaney VA, Thibadoux G, Hayes FA, Green AA. Hearing loss in children receiving cisplatin chemotherapy. Journal of Pediatrics 1983; 102: 314-17.
38. Merrin C. Treatment of advanced bladder cancer with cis-diammenochloroplatinum. Journal of Urology 1978; 119: 493-5.
39. Moore M, Erlichman C. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clinical Pharmacokinetics 1987; 13: 892-5.
40. Park RK. The utility of acoustic reflex thresholds and other conventional audiologic tests for monitoring cisplatin ototoxicity in the pediatric population. Ear and Hearing 1996; 17: 107-15.
41. Pasic RT, Dobie AR. Cis-Platinum ototoxicity in children. Laryngoscope 1991; 101: 985-91.
42. Plinkert PK, Krober S. Early detection of cisplatinum ototoxicity by otoacoustic emissions. Laryngo-Rhino-Otologie 1991; 70: 457-62.
43. Pollera CF, Marolla P, Nardi M, Ameglio F, Cozzo L, Bevere F. Very high-dose cisplatin-induced ototoxicity: A preliminary report on early and long-term effects. Cancer Chemotherapy and Pharmacology 1988; 21(1): 61-4.
44. Probst R. Otoacoustic emissions: An overview. Advances in Otolaryngology 1989; 44: 1-91.
45. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: Antioxidant system. Pharmacology and Toxicology 1996; 76: 386-94.
46. Riggs LC, Brummett RE, Guitjens SK, Matz GJ. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope 1996; 106: 401-6.
47. Ruiz L, Gilden J, Jaffe N, Robertson R, Wang YM. Auditory function in pediatric osteosarcoma petients treated with multiple doses of cis-diamminedichloroplatinum (II). Cancer Research 1989; 49: 742-4.
48. Saito T, Aran J-M. Comparative ototoxicity of cisplatin during acute and chronic treatment. ORL; Journal of Oto-Rhino-Laryngology and its Related Specialties 1994; 56: 315-20.
49. Saito T, Moataz R, Dulon D. Cisplatin blocks depolarisation-induced calcium entry in isolated cochlear hair cells. Hearing Research 1991; 56: 143-7.
50. Santi PA, Duvall (III) AJ. Morphological alteration of the stria vascularis after administration of the diuretic bumetanide. Acta Otolaryngologica 1979; 88: 1-12.
51. Schweitzer VG. Ototoxicity of chemotherapeutic agents. Otolaryngologic Clinics of North America 1993; 26(5): 759-89.
52. Schweitzer VG, Hawkins JE, Lilly DJ, Litterst CJ, Abrams G, Davies JA, Christy M. Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kenamicin in the guinea pig. Otolaryngology, Head and Neck Surgery 1984; 92: 38-49.
53. Shepherd RK, Clark, GM. Progressive ototoxicity of neomycin monitored using derived brain-stem response audiometry. Hearing Research 1985; 18: 105-10.
54. Simpson TH, Schwan SA, Rintelman WF. Audiometric test criteria in the detection of cisplatin ototoxicity. Journal of the American Academy of Audiology 1992; 3, 176-85.
55. Sims MH, Robert RK, James TW. Transiently evoked otoacoustic emissions in dogs. Journal of Veterinary Neurology 1994; 5(25): 49-56.
56. Skinner R, Pearson ADJ, Ameneddine HA, Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents. British Journal of Cancer 1990; 61: 927-31.
57. Strauss M, Towfighi J, Lord S, Lipton A, Harvey HA, Brown, B. Cisplatinum ototoxicity: Clinical experience and temporal bone histopathology. Laryngoscope 1983; 93: 1554-9.
58. Stadnicki SW, Fleischman RW, Scheppi U, Merrian P. Cisdichlorodiammine platinum (II): Hearing loss and other toxic effects in Rhesus monkeys. Cancer Chemotherapy Reports 1975; 59: 467-80.
59. Tange RA, Vuzevski VD. Changes in the stria vascularis of the guinea pig due to cisplatinum. Archives of Otolaryngology 1984; 239: 41-7.
60. Taudy M, Syka J, Popelar J, Ulehloua L. Carboplatinum and cisplatin ototoxicity in guinea pigs. Audiology 1992; 31: 293-9.
61. Van der Hulst RJ, Dreschler WA, Urbanus NAM. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Annals of Otology, Rhinology and Laryngology 1988; 97: 133-7.
62. Vermorken JB, Kapteyn TS, Hart AAN, Pinedo HM. Ototoxicity of cis-diamminedichloroplatinum II. Influence of dose, schedule and mode of administration. European Journal of Cancer and Clinical Oncology 1983; 19: 53-8.
63. Waters SG, Ahmad M, Katsarkas A, Stanimir G, Mckay J. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: Influence of dosage and schedule of administration. Ear and Hearing 1991; 12(2): 91-102.
64. Weatherly AR, Owens JJ, Catlin IF, Mahoney HD. Cis-platinum ototoxicity in children. Laryngoscope 1991; 101: 917-24.
65. Wright CG, Schaeffer SD. Inner ear histopathology in patients treated with cisplatinum. Laryngoscope 1982; 92: 1408-13.
66. Zheng X-Y, Wang J, Salvi R, Henderson D. Effects of kainic acid on the cochlear potentials and distortion product otoacoustic emissions in chinchilla. Hearing Research 1996; 95: 161-7.
67. Zorowka PG, Schmitt HJ, Gutjahr P. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy. International Journal of Pediatric Otorhinolaryngology 1993; 25: 73-80.